DSM closes citric acid plant
This article was originally published in The Tan Sheet
Executive Summary
The Netherlands-based life and material sciences firm will close its Wuxi, China citric acid manufacturing plant by the first quarter of 2009, DSM announces Aug. 15. The closure comes after a request from the local government to relocate the plant because its current location is slated for urban development, DSM says. The firm does not expect to incur a loss due to the closing of the plant since the Wuxi government compensated DSM. The company decided not to rebuild the plant, but to relocate operations to its Tienen, Belgium site. ... Invests in Provexis: DSM Venturing acquires a 29.3 percent equity stake in Provexis, a development and licensing firm for functional food ingredients, medical foods and supplements. "The investment is in line with DSM's strategy to further expand in ingredients for functional food and dietary supplements focusing on, for example, cardiovascular and digestive health, two areas also addressed by Provexis," DSM says in an Aug. 27 release. Provexis' lead product is FruitFlow, a biotactive from tomato extract that improves blood flow for cardiovascular health, DSM says. Several large food manufacturers, including Unilever, have expressed interest in the ingredient, the firm says
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.